{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:13:11Z","timestamp":1788264791111,"version":"build-2803163510"},"reference-count":24,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["80102022624"],"award-info":[{"award-number":["80102022624"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Background: Globally, lung cancer is the foremost contributor to cancer-associated fatalities. Of its various histological sub-types, non-small-cell lung cancer (NSCLC) constitutes the vast majority, accounting for more than 85% of diagnoses. A key driver in this pathology is the mesenchymal\u2013epithelial transition (MET) receptor tyrosine kinase, whose biological activity is governed by the hepatocyte growth factor (HGF) ligand. MET plays a pivotal role in regulating tumour cell proliferation and migration, and aberrant activation of MET signalling is linked to the pathogenesis of NSCLC.\n\nMethods: A retrospective analysis of the FAERS database (2016\u20132025) was conducted to obtain adverse event data pertaining to four MET-targeted therapeutic agents, namely amivantamab, savolitinib, capmatinib and tepotinib. A systematic disproportionality analysis was performed to identify adverse events.\n\nResults: Statistically significant differences were observed across most baseline clinical characteristics. Patients taking tepotinib were significantly older (mean 74.7 years) and experience a higher mortality (21%) than those taking amivantamab, savolitinib or capmatinib. In signal detection, amivantamab caused severe cutaneous\/ mucosal and infusion-related toxicities. The three c-Met inhibitors led to oedema, with savolitinib distinguished by haematological risks, capmatinib by severe oedema and tepotinib by pulmonary\/renal toxicities. In time-toonset analysis, amivantamab\u2019s infusion-related reaction occurred earliest with the highest incidence; savolitinib (pyrexia\/hepatic abnormalities) and capmatinib (nausea) appeared early with relatively high incidences; tepotinib\u2019s peripheral swelling was early but had a low incidence. High death-associated adverse drug reactions included dyspnoea, peripheral oedema, decreased appetite and increased creatinine, warranting further investigation. In cluster analysis, key adverse drug reactions (e.g. infusion-related reactions for amivantamab, hepatotoxicity for savolitinib, peripheral swelling for capmatinib and peripheral oedema for tepotinib) primarily occur as isolated events with limited co-occurrence of multiple toxicities.\n\nConclusion: These findings support individualized monitoring and evidence-based treatment selection for older patients, those with comorbidities or patients at high risk with MET-altered NSCLC.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-real-world-safety-assessment-of-met-targeted-therapies-a-pharmacovigilance-analysis-using-the-faers-database<\/jats:p>","DOI":"10.7573\/dic.2026-4-7","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:17:45Z","timestamp":1788261465000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety assessment of MET-targeted therapies: a pharmacovigilance analysis using the FAERS database"],"prefix":"10.7573","author":[{"given":"Ning","family":"Li","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"publisher"}],"name":"Chinese Academy of Medical Sciences & Peking Union Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Cong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"publisher"}],"name":"Chinese Academy of Medical Sciences & Peking Union Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Yang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"publisher"}],"name":"Chinese Academy of Medical Sciences & Peking Union Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tSiegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043. https:\/\/doi.org\/10.3322\/caac.70043","DOI":"10.3322\/caac.70043"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tSu PL, Furuya N, Asrar A, et al. Recent advances in therapeutic strategies for non-small cell lung cancer. J Hematol Oncol. 2025;18(1):35. https:\/\/doi.org\/10.1186\/s13045-025-01679-1","DOI":"10.1186\/s13045-025-01679-1"},{"key":"ref2","unstructured":"3.\tWang J, Ma R, Qu B, Li X. Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system. Expert Opin Drug Saf. 2025:1\u201310. https:\/\/doi.org\/10.1080\/ 14740338.2025.2487158"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tRemon J, Hendriks LEL, Mountzios G, et al. MET alterations in NSCLC-current perspectives and future challenges. J Thoracic Oncol. 2023;18(4):419\u2013435. https:\/\/doi.org\/10.1016\/j.jtho.2022.10.015","DOI":"10.1016\/j.jtho.2022.10.015"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tLee JB, Shim JS, Cho BC. Evolving roles of MET as a therapeutic target in NSCLC and beyond. Nat Rev Clin Oncol. 2025;22(9):640\u2013666. https:\/\/doi.org\/10.1038\/s41571-025-01051-9","DOI":"10.1038\/s41571-025-01051-9"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tDrusbosky LM, Dawar R, Rodriguez E, Ikpeazu CV. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer. J Hematol Oncol. 2021;14(1):129. https:\/\/doi.org\/10.1186\/s13045-021-01138-7","DOI":"10.1186\/s13045-021-01138-7"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tYang J, Li N, Lin W, et al. Machine learning for predicting hyperglycemic cases induced by PD-1\/PD-L1 inhibitors. J Healthcare Eng. 2022;2022:6278854. https:\/\/doi.org\/10.1155\/2022\/6278854","DOI":"10.1155\/2022\/6278854"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tYang J, Li N, Lin W, et al. Comprehensive analysis of diabetes mellitus-related gene expression and associated prognoses in human lung cancer. Curr Cancer Drug Targets. 2023;23(11):889\u2013899. https:\/\/doi.org\/ 10.2174\/1568009623666230529154306","DOI":"10.2174\/1568009623666230529154306"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tZeng Y, Li Y, Du Z, Shu R, Fu C, Zeng Q. Cutaneous adverse events associated with Rybrevant based on FDA adverse event reporting system (FAERS) database from 2021 to 2024. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2026;399:12157\u201312168. https:\/\/doi.org\/10.1007\/s00210-026-05168-1","DOI":"10.1007\/s00210-026-05168-1"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tFu X, Zeng D, Li M, et al. Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system. Expert Opin Drug Saf. 2025;26:1\u20139. https:\/\/doi.org\/10.1080\/14740338.2025.2471512","DOI":"10.1080\/14740338.2025.2471512"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tSun R, Ning Z, Qin H, et al. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database. Sci Rep. 2024;14(1):9552. https:\/\/ doi.org\/10.1038\/s41598-024-55829-5","DOI":"10.1038\/s41598-024-55829-5"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tLu KV, Chang JP, Parachoniak CA, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex. Cancer Cell. 2012;22(1):21\u201335. https:\/\/doi.org\/10.1016\/j.ccr.2012.05.037","DOI":"10.1016\/j.ccr.2012.05.037"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tChen TT, Filvaroff E, Peng J, et al. MET Suppresses epithelial VEGFR2 via intracrine VEGF-induced endoplasmic reticulum-associated degradation. EBioMedicine. 2015;2(5):406\u2013420. https:\/\/doi.org\/10.1016\/j.ebiom.2015.03.021","DOI":"10.1016\/j.ebiom.2015.03.021"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tLin Y, Xu S, Deng M, Cao Y, Ding J, Lin T. Exploring ototoxicity associated with capmatinib: insights from a real-world data analysis of the FDA adverse event reporting system (FAERS) database. Clin Epidemiol. 2025;17:513\u2013521. https:\/\/ doi.org\/10.2147\/clep.S528454","DOI":"10.2147\/CLEP.S528454"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tChang X, Shao D, Bao J, Liu Z, Ma J. Comparative toxicovigilance of capmatinib and tepotinib in NSCLC: respiratory signal detection and adverse event profiling via FAERS. J Biochem Mol Toxicol. 2026;40(1):e70657. https:\/\/doi.org\/ 10.1002\/jbt.70657","DOI":"10.1002\/jbt.70657"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tWei S, Zhang L, Liu C, Qi X. Real-world safety of tepotinib: insights from the food and drug administration adverse event reporting system. PLoS One. 2025;20(12):e0339005. https:\/\/doi.org\/10.1371\/journal.pone.0339005","DOI":"10.1371\/journal.pone.0339005"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tLu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 2021;9(10):1154\u20131164. https:\/\/doi.org\/10.1016\/s2213-2600(21)00084-9","DOI":"10.1016\/S2213-2600(21)00084-9"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tChoueiri TK, Heng DYC, Lee JL, et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 2020;6(8):1247\u20131255. https:\/\/doi.org\/10.1001\/ jamaoncol.2020.2218","DOI":"10.1001\/jamaoncol.2020.2218"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tLee J, Kim ST, Kim K, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discovery. 2019;9(10):1388\u20131405. https:\/\/doi.org\/10.1158\/2159-8290. Cd-19-0442","DOI":"10.1158\/2159-8290.CD-19-0442"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tYoh K, Hirashima T, Saka H, et al. Savolitinib \u00b1 osimertinib in Japanese patients with advanced solid malignancies or EGFRm NSCLC: Ph1b TATTON part C. Target Oncol. 2021;16(3):339\u2013355. https:\/\/doi.org\/10.1007\/s11523-021-00806-5","DOI":"10.1007\/s11523-021-00806-5"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tChoueiri TK, Plimack E, Arkenau HT, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017;35(26):2993\u20133001. https:\/\/doi.org\/10.1200\/jco.2017.72.2967","DOI":"10.1200\/JCO.2017.72.2967"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tZheng R, Chen J, Han J, et al. A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk. Ren Fail. 2026;48(1):2610895. https:\/\/doi.org\/ 10.1080\/0886022x.2025.2610895","DOI":"10.1080\/0886022X.2025.2610895"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tChen MF, Harada G, Liu D, et al. Brief report: tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to \u201cfalse\u201d decreases in renal function. J Thoracic Oncol. 2024;19(1):153\u2013159. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.1444","DOI":"10.1016\/j.jtho.2023.09.1444"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tWijtvliet V, Roosens L, De Bondt C, Janssens A, Abramowicz D. Pseudo-acute kidney injury secondary to tepotinib. Clin Kidney J. 2023;16(4):760\u2013761. https:\/\/doi.org\/10.1093\/ckj\/sfac180","DOI":"10.1093\/ckj\/sfac180"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/09\/dic.2026-4-7.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:17:48Z","timestamp":1788261468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/real-world-safety-assessment-of-met-targeted-therapies-a-pharmacovigilance-analysis-using-the-faers-database"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-4-7","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"dic.2026-4-7"}}